We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00742079
Recruitment Status : Completed
First Posted : August 27, 2008
Results First Posted : September 5, 2014
Last Update Posted : December 19, 2017
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Donald C. Goff, MD, Massachusetts General Hospital

Brief Summary:
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: D-cycloserine Behavioral: Cognitive Behavioral Therapy Phase 4

Detailed Description:

Schizophrenia is a debilitating chronic condition that affects approximately 1 % of Americans, who experience symptoms such as hallucinations, delusions, and disorders of thought and movement. These symptoms are described as positive symptoms, because they are experienced in addition to what healthy individuals experience. Negative symptoms, which are reductions in normal functioning, and cognitive deficits, which are problems in thinking, also plague people with schizophrenia. The negative symptoms and cognitive deficits associated with schizophrenia are produced in otherwise healthy people by neurotransmitters inhibiting the glutamatergic N-methyl-d-aspartate NMDA receptors in the brain. This inhibition of NMDA receptors also causes intensification of psychotic symptoms in otherwise stabilized schizophrenic patients. The drug D-cycloserine partially excites NMDA receptors, and it has been used to help patients with anxiety disorders to overcome phobias while they are receiving cognitive behavioral therapy. This study will examine whether D-cycloserine can increase the cognitive flexibility of someone undergoing CBT and thereby enhance the therapy's ability to reduce a patient's belief in paranoid delusions, preoccupation with delusions, and related distress.

All participants will be screened to ensure proper diagnosis of schizophrenia without other conditions. Those who pass will be randomly assigned to receive either D-cycloserine first or a placebo pill first. One week after the screening, participants in the D-cycloserine group will be given the drug before a 1-hour session of simulated CBT treatment. Those in the placebo condition will receive a placebo pill before an identical session. Two weeks after the screening, both groups will be called back for another session of CBT, but the pills they receive will be switched. Those who received D-cycloserine the first week will receive placebo, and those who received placebo will receive D-cycloserine. The CBT sessions will attempt to increase cognitive flexibility in patients by asking them to provide alternate explanations for common situations. At screening, at the start of visits on the first and second weeks, and at a follow-up visit on the third week, participants will undergo a series of assessments, including interviews, computerized tests, and self-report measures. Belief in, preoccupation with, and distress caused by delusions, as well as degree of cognitive flexibility, will be assessed.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia
Study Start Date : September 2006
Primary Completion Date : July 2010
Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Cycloserine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 D-cycloserine, placebo
Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
Drug: D-cycloserine
Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Other Name: Seromycin
Behavioral: Cognitive Behavioral Therapy
One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Other Name: CBT
Experimental: 2 Placebo, D-cycloserine
Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
Drug: D-cycloserine
Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Other Name: Seromycin
Behavioral: Cognitive Behavioral Therapy
One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Other Name: CBT



Primary Outcome Measures :
  1. Change in Alternative Beliefs Assessment [ Time Frame: Baseline to Week 2 ]
    Number of alternative beliefs generated on the Alternative Beliefs Assessment. This assessment used nine vignettes describing social interactions: three of neutral content, three negatively-valanced, and three tailored to the patient's specific delusions. Participants were asked to generate as many explanations (alternative beliefs) as they could for each scenario, and the number of explanations produced in response to each item was recorded. Scores could range from 0 to as many explanations a person could produce (no maximum value). The total score was calculated by adding all alternative beliefs generated from each vignette. A higher number of alternative beliefs generated reflects a greater degree of cognitive flexibility.


Secondary Outcome Measures :
  1. Change in Psychotic Rating Scales (PSYRATS) Delusion Score [ Time Frame: Baseline to Week 2 ]
    The Delusions subscale is a 6 item clinician administered scale, with Likert items 0-4 and range is 0-24. Higher scores represent worse outcomes

  2. Change in Beck Cognitive Insight Scale (BCIS) [ Time Frame: Baseline to Week 2 ]

    The BCIS is a 15-item self-report scale with Likert items 0-3. It consists of a composite score, where higher scores represent better outcomes, and there are 2 subscales: 1) Self-Reflectiveness (higher scores represent better outcomes) and 2) Self-Certainty (higher scores represent worse outcomes). The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty.

    Step 1. Score every item on the BCIS from "0" to "3" according to the following rule:

    "Do Not Agree at All" = 0, "Agree Slightly" = 1, "Agree a Lot" = 2, "Agree Completely" = 3 Step 2. Calculate self-reflectiveness subscale: sum items 1, 3, 4, 5, 6, 8, 12, 14, and 15.

    Step 3. Calculate self-certainty subscale: sum items 2, 7, 9, 10, 11, and 13. Step 4. Calculate BCIS composite index: self-reflectiveness minus self-certainty.


  3. Change in Bead Task Score Measuring Probabilistic Reasoning [ Time Frame: Baseline to Week 2 ]
    The Bead task is a reasoning task, where the number of beads guessed is the numeric value represented in the data. The lower end range is 1, and there is no upper range limit. Higher scores represent better outcomes.

  4. Change in the Maudsley Assessment of Delusions Scale [ Time Frame: Baseline to Week 2 ]
    This scale is a one-question item added on to the Bead Task. The one item asks for a certainty rating, from 1-3. Higher scores represent better outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meets DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophrenia, paranoid subtype, based on chart review, Structured Clinical Interview for DSM-IV, and consultation with the patient's clinicians
  • Medicated with an antipsychotic agent other than clozapine at a stable dose for at least 6 weeks
  • Scores at least 3, or "moderate," on the Scale for the Assessment of Positive Symptoms global delusion rating
  • Paranoid or referential delusional content
  • Never engaged in formal CBT psychotherapy in the past

Exclusion Criteria:

  • Diagnosis of a comorbid Axis I disorder other than schizophrenia
  • Active substance abuse or dependence within 6 months
  • Significant suicidal ideation within 6 weeks
  • Pregnant or nursing
  • Unstable medical disorder
  • impaired renal clearance (creatinine <60mg/dL/min)
  • Suffering from dementia
  • Suffering from seizure disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00742079


Locations
United States, Massachusetts
MGH Schizophrenia Program - Freedom Trail Clinic
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Donald C. Goff, MD Massachusetts General Hospital

Publications:
Responsible Party: Donald C. Goff, MD, Director of the Schizophrenia Clinical and Research Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00742079     History of Changes
Other Study ID Numbers: P50MH060450 ( U.S. NIH Grant/Contract )
2P50MH060450-07A1 ( U.S. NIH Grant/Contract )
DATR A3-NSC ( Other Grant/Funding Number: National Institute of Mental Health )
First Posted: August 27, 2008    Key Record Dates
Results First Posted: September 5, 2014
Last Update Posted: December 19, 2017
Last Verified: September 2014

Keywords provided by Donald C. Goff, MD, Massachusetts General Hospital:
Paranoid Schizophrenia
Paranoid Delusions
CBT
D-Cycloserine

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Cycloserine
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action